Evidence map›Paper›PMID 42900447›Full record

ArticleLifetime data analysis2026

Dynamic risk assessment by landmark modeling of the restricted residual mean survival time.

Yuan Zhang, Douglas E Schaubel

Abstract read
In one paragraph

Article in Lifetime data analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuan ZhangDivision of Biostatistics, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7626-9514
Douglas E SchaubelDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. douglas.schaubel@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-9792-4474

Funding

NIDDK NIH HHS R01-DK070869
6 · The paper itself

Abstract

Dynamic risk assessment is an important tool for healthcare providers to inform treatment selection and optimize patient outcomes. Frequent evaluation of clinical status provides invaluable information on adverse event risk and/or treatment urgency, based on the changes in predictive biomarkers. Landmark analysis is a useful approach for dynamic risk assessment that obviates the complexity of jointly modeling longitudinal covariates and time-to-event outcome. Traditional landmark methods often rely on the proportional hazards assumption and assume independent censoring. We propose novel methods to broaden the scope of landmark analysis by directly modeling the restricted residual mean survival time (RRMST) at each landmark date while accommodating dependent censoring. Advantages of RMST models include removing the assumption that the (hazard) model is correct at every time point; RMST models instead consider a single capped survival time. Moreover, investigators may prefer the area under the survival curve to the hazard function as a metric in terms of interpretability. We derive the asymptotic properties of our proposed estimators and validate their performance in finite samples through extensive simulations. We apply the proposed methods to analyze outcomes under natural end-stage liver disease (ESLD) history (i.e., in the absence of liver transplantation).

Indexed as

Models, StatisticalComputer SimulationEnd Stage Liver DiseaseHumansLiver TransplantationProportional Hazards ModelsRisk AssessmentSurvival AnalysisDependent censoringLandmark analysisLiver transplantNon-proportional hazardsRestricted mean survival timeTime-varying covariate

Identifiers

PMID42900447
PMCPMC13683509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.